Nurexone Biologic Inc Stock Price, News & Analysis

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced significant advancements in their exosome manufacturing process, important for their ExoPTEN product development. The company demonstrated consistent exosome production from multiple biological sources, comparing exosomes from bone marrow-derived mesenchymal stem cells (MSCs) of different donors. Despite natural variability in starting materials, the exosomes showed consistent yields and similar size distribution.

NurExone also tested the effectiveness of exosomes in an animal model of spinal cord injury, demonstrating excellent and comparable homing abilities to the injured area. The company compared exosomes produced using 2D and 3D culture methods, finding similar homing and targeting capabilities. This advancement supports NurExone's ability to scale up production for potential commercial applications in regenerative medicine treatments.

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has announced new data for its ExoPTEN nanodrug, demonstrating significant progress towards commercial-grade manufacturing. The study focused on ExoPTEN's ability to target inflammation and injury sites when loaded with small interfering RNA (siRNA) produced by a new GMP-compliant manufacturer.

Key findings include:

• ExoPTEN showed exceptional homing capacity to injured spinal cord tissue in rats
• High concentration of the drug was observed in damaged tissue
• Results validate the quality of siRNA from the new GMP Partner
• Confirms NurExone's exosomes as an effective drug delivery system

This advancement marks a important step towards meeting quality and regulatory standards for commercial manufacturing, as the company progresses towards clinical trials.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced a significant milestone in its regenerative medicine efforts. The company has successfully transferred the manufacturing of the siRNA sequence for its ExoPTEN nanodrug to a German GMP-capable producer. This move is important for producing drugs for clinical trials and commercial sale.

The siRNA from the new vendor achieved an approximately 80% reduction in PTEN expression, demonstrating comparable potency to the previous research-grade producer. This transfer establishes the foundation for future GMP manufacture of NurExone's patented product, which uses PTEN inhibition to facilitate nerve growth and regeneration after injury or damage.

Dr. Lior Shaltiel, CEO of NurExone, emphasized the importance of this achievement in meeting the strict quality and regulatory standards necessary for clinical trials, marking a critical step in the development of the ExoPTEN nanodrug.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced the expansion of its ExoPTEN patent coverage. The Israel Patent Office issued a Notice of Allowance for a patent titled 'Vesicles Comprising a PTEN Inhibitor and Uses of Same', which covers innovative Extracellular Vesicles (EVs) with a PTEN inhibitor. This patent is important for NurExone's ExoPTEN drug, aimed at promoting nerve growth and regeneration after acute spinal cord injury.

The company also revealed its engagement with Allele Capital Partners, for investor relation services, including capital markets consultation and corporate video dissemination on social media. The initial agreement is for one month at $11,000 per month, with potential for extension and a fee increase to $14,500 upon uplisting to NYSE or NASDAQ.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced promising preliminary results from a small-scale study exploring the use of its nanodrug, ExoPTEN, for optic nerve recovery in a rat model at Sheba Medical Center. The study, using an Optic Nerve Crush (ONC) model to simulate glaucoma conditions, showed that ExoPTEN treatment resulted in functional restoration of damaged eyes to healthy levels.

Key findings include:

• ExoPTEN-treated eyes exhibited retinal response similar to healthy eyes
• Results were observed just 18 days after ONC damage
• Treatment was administered minimally-invasively using suprachoroidal injection

These preliminary results suggest potential for ExoPTEN in the $3.4 billion glaucoma market, with further studies planned to validate findings and explore human applications.

NurExone Biologic has announced two key updates to enhance its mission and stakeholder engagement.

CEO Dr. Lior Shaltiel will be presenting at the Emerging Growth Conference – Biotech Feature on July 18, 2024, from 2:55pm to 3:25pm ET.

Dr. Shaltiel will discuss the company's innovative ExoTherapy platform and the development of ExoPTEN for acute spinal cord injuries.

Additionally, NurExone has relaunched its website to offer a clearer, more intuitive interface, aiming to improve communication with collaborators, pharmaceutical companies, and other stakeholders.

For more details, visit www.nurexone.com.

NurExone Biologic announced a pre-clinical study to explore the regenerative potential of its exosome-based therapies on damaged optic nerves. The study, led by prominent ophthalmologists from Sheba Medical Center, aims to address the US$3.4 billion optic nerve disorders treatment market.

Current treatments focus on preventing further damage rather than regeneration. NurExone's exosome-loaded drugs could offer a new solution, based on their success in spinal cord trials. The market is projected to grow to US$5.3 billion by 2031, with key players including AbbVie, Novartis, Santen, and Teva.

The study is a part of NurExone's broader strategy to expand clinical indications for their ExoTherapy platform, with the goal of improving quality of life for those affected by optic nerve injuries and diseases.

NurExone Biologic announced the engagement of Dr. Yona Geffen as a consultant to enhance its preclinical and clinical activities. Dr. Geffen, an experienced expert from Gamida Cell, will aid in developing Chemistry, Manufacturing, and Controls (CMC) and ensure compliance with Good Manufacturing Practices (GMP). She will contribute to optimizing dosing regimens, developing analytical methods, and qualifying potency assays. This collaboration aims to advance NurExone's ExoPTEN nanodrug for spinal cord injury.

NurExone Biologic announces the Japan Patent Office's issuance of a Notice of Allowance for the ExoPTEN patent, which covers innovative extracellular vesicles comprising a PTEN inhibitor. The ExoPTEN drug aims to promote nerve growth and regeneration after acute spinal cord injury. This patent, licensed from Technion, marks a significant step for NurExone's technology in the Asian market and follows corresponding approvals in the USA and Russia. Additionally, the company extended its investor relations agreement with BullVestor Medien until May 2025, aiming to boost awareness in German-speaking countries.